乌干达农村学龄儿童疟疾间歇性预防治疗(双氢青蒿素-哌喹)对疫苗特异性应答的影响(POPVAC B):双盲随机对照试验
在乌干达金贾区两所学校9-17岁学龄儿童中开展个体随机双盲安慰剂对照试验,评估每月双氢青蒿素-哌喹间歇性预防治疗对疫苗应答的影响。共随机分配341人(双氢青蒿素-哌喹组170人,安慰剂组171人)。双氢青蒿素-哌喹降低了疟疾患病率,但对BCG、黄热病、伤寒、HPV、破伤风-白喉疫苗的主要应答指标均无显著影响;有部分证据提示可减少黄热病应答的衰减。
要点
- 双氢青蒿素-哌喹组入组时疟疾患病率64%,随访期间降至6%或以下。
- 对BCG特异性IFNγ ELISpot应答的几何平均比(GMR)为1.09(95%CI 0.93-1.29),p=0.28。
- 对黄热病中和抗体PRNT50滴度GMR为1.19(95%CI 0.91-1.54),p=0.20。
核心结论
- 双氢青蒿素-哌喹间歇性预防治疗虽降低疟疾患病率,但未改善疫苗应答峰值;对黄热病应答衰减的可能长期影响应进一步探索。
研究设计与样本
- 在乌干达金贾区两所学校开展个体随机、双盲、安慰剂对照试验,纳入9-17岁学龄儿童341人,按1:1随机分配至双氢青蒿素-哌喹组(170人)或安慰剂组(171人)。
- 每月给予3天疗程双氢青蒿素-哌喹(按体重给药)或安慰剂,包括首次疫苗接种前两次。
- 主要结局为第8周疫苗应答及破伤风-白喉第52周应答,在意向治疗人群中分析。
主要发现
- 入组时双氢青蒿素-哌喹组109/170(64%)和安慰剂组99/170(58%) participants有疟疾,双氢青蒿素-哌喹组所有随访访视时降至6%或以下。
- BCG特异性IFNγ ELISpot应答的几何平均比(GMR)为1.09(95%CI 0.93-1.29),p=0.28。
- 黄热病中和抗体PRNT50滴度GMR为1.19(95%CI 0.91-1.54),p=0.20;PRNT90滴度GMR为1.24(95%CI 0.97-1.58),p=0.09。
- 伤寒沙门菌Typhi O-脂多糖IgG GMR为1.09(95%CI 0.81-1.46),p=0.58;HPV-16 IgG GMR为0.72(95%CI 0.44-1.77),p=0.19;HPV-18 IgG GMR为0.71(95%CI 0.47-1.09),p=0.11;破伤风类毒素GMR为1.22(95%CI 0.91-1.62),p=0.18;白喉类毒素GMR为0.97(95%CI 0.83-1.13),p=0.72。
- 有部分证据提示双氢青蒿素-哌喹减少了黄热病应答的衰减。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several important vaccines differ in immunogenicity and efficacy between populations. We hypothesised that malaria suppresses responses to unrelated vaccines and that this effect can be reversed-at least partially-by monthly malaria intermittent preventive treatment (IPT) in high-transmission settings. METHODS: We conducted an individually randomised, double-blind, placebo-controlled trial of the effect of malaria IPT with dihydroartemisinin-piperaquine on vaccine responses among schoolchildren aged 9-17 years in Jinja district, Uganda. Participants were recruited from two schools and did not have exposure to vaccines of interest after the age of 5 years, with the exception of human papillomavirus (HPV). Computer-generated 1:1 randomisation was implemented in REDCap. 3-day courses of dihydroartemisinin-piperaquine (dosage by weight) or placebo were administered monthly, including twice before the first vaccination. Trial participants were vaccinated with the live parenteral BCG vaccine (Serum Institute of India, Pune, India) at week 0; yellow fever vaccine (YF-17D; Sanofi Pasteur, Lyon, France); live oral typhoid vaccine (Ty21a; PaxVax, London, UK), and quadrivalent virus-like particle HPV vaccine (Merck, Rahway, NJ, USA) at week 4; and toxoid vaccines (tetanus-diphtheria; Serum Institute of India) and an HPV booster at week 28. An additional HPV vaccination at week 8 was provided to female participants older than 14 years who had not previously been vaccinated, and a tetanus-diphtheria booster was given after completion of the trial at week 52. Primary outcomes were vaccine responses at week 8 and, for tetanus-diphtheria, at week 52, and analysis was done in the intention-to-treat population. Malaria parasite prevalence at enrolment and during follow-up was determined retrospectively by PCR. The safety population comprised all randomly allocated participants. The trial was registered at the ISRCTN Registry (ISRCTN62041885) and is complete. FINDINGS: Between May 25 and July 14, 2021, we assessed 388 potential participants for eligibility. We enrolled and randomly allocated 341 participants to the two groups (170 [50%] to dihydroartemisinin-piperaquine and 171 [50%] to placebo); 192 (56%) were female and 149 (44%) participants were male. 145 (85%) participants in the dihydroartemisinin-piperaquine group and 140 participants (82%) in the placebo group were followed up until the week 52 endpoint. At enrolment, 109 (64%) of all participants in the dihydroartemisinin-piperaquine group and 99 (58%) of 170 participants in the placebo group had malaria; this reduced to 6% or lower at all follow-up visits in the dihydroartemisinin-piperaquine group. There was no effect of dihydroartemisinin-piperaquine versus placebo on primary outcomes: BCG-specific IFNγ ELISpot response had a geometric mean ratio (GMR) of 1·09 (95% CI 0·93-1·29), p=0·28; yellow fever neutralising antibody was 1·19 (0·91-1·54), p=0·20 for plaque reduction neutralising reference tests (PRNT50) titres (the reciprocal of the last plasma dilution that reduced by 50%) and 1·24 (0·97-1·58), p=0·09 for PRNT90 titres (reciprocal of the last plasma dilution that reduced by 90%); and IgG to Salmonella enterica serovar Typhi O-lipopolysaccharide was 1·09 (0·81-1·46), p=0·58, HPV-16 was 0·72 (0·44-1·77), p=0·19, HPV-18 was 0·71 (0·47-1·09), p=0·11; tetanus toxoid was 1·22 (0·91-1·62), p=0·18, and diphtheria toxoid was 0·97 (0·83-1·13), p=0·72. There was some evidence that dihydroartemisinin-piperaquine reduced waning of the yellow fever response. INTERPRETATION: IPT for malaria with dihydroartemisinin-piperaquine did not improve peak vaccine responses, despite reducing malaria prevalence. Possible longer-term effects on response waning should be further explored. FUNDING: UK Medical Research Council. TRANSLATION: For the Luganda translation of the abstract see Supplementary Materials section.
引用
- Zirimenya L, Natukunda A, Nassuuna J, et al. The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda (POPVAC B): a double-blind, randomised controlled trial. Lancet Glob Health. 2024. PMID: 39424572. doi:10.1016/S2214-109X(24)00281-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。